CSTL — Castle Biosciences Inc
NASDAQ · Healthcare · Diagnostics & Research
$33.88
+$0.44 (+1.30%)
Castle Biosciences Inc (CSTL) is a diagnostics & research company listed on NASDAQ. It is led by Derek J. Maetzold, based in 505 S. Friendswood Drive, Friendswood, TX, United States, 77546, with about 784 employees. Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Latest reported CSTL revenue for 2025-09-30 was $83.0M. Net income was -$501.0K. Revenue was down 3.6% from 2025-06-30 to 2025-09-30. CSTL currently screens at market cap $570.2M.
Use this CSTL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CSTL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CSTL SEC filings page. Lician reads the product cache first so this HTML stays unique to Castle Biosciences Inc even when a live quote feed is slow.
About Castle Biosciences Inc
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a risk stratification spatial-omics test to predict future development of progression of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide optimal drug treatment for patients diagnosed with major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. The company offers its products to skin cancer and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
CSTL Key Statistics
Market Cap
$570.23M
Volume
62,490
Previous Close
$33.47
Day Range
$33.29 – $34.79
EPS
$0.62
Revenue
$332.07M
Net Income
$18.25M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+51.1%
Profit Margin
5.5%
Employees
784
CSTL Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $332.07M | $219.79M | $137.04M | $94.08M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $18.25M | -$57.47M | -$67.14M | -$31.29M |
| EPS (Diluted) | $0.62 | -$2.14 | -$2.58 | -$1.24 |
Total Assets
$531.24M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$119.71M
Operating Cash Flow
$64.87M
Free Cash Flow
$0.00
Castle Biosciences Inc Company Information
- Founder, CEO, President & Director
- Derek J. Maetzold
- Headquarters
- 505 S. Friendswood Drive, Friendswood, TX, United States, 77546
- Website
- castlebiosciences.com
- Phone
- 866 788 9007
- IPO / Founded
- 2019-07-25
- Sector
- Healthcare
- Industry
- Diagnostics & Research